sameAs
Screening for chronic comorbid diseases in people with HIV: the need for a strategic approachImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, CanadaPredictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapyThe CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recoveryPreparedness for use of the rapid result HIV self-test by gay men and other men who have sex with men (MSM): a mixed methods exploratory study among MSM and those involved in HIV prevention and careEpidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study.Acute systemic inflammation induced by influenza A (H1N1) vaccination causes a deterioration in endothelial function in HIV-infected patients.Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey.Nurse-delivered universal point-of-care testing for HIV in an open-access returning traveller clinic.Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.Pregnancy complications in HIV-positive women: 11-year data from the Frankfurt HIV Cohort.The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system.Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events ofEfficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study.Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility.Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis.Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.Hepatitis C in men who have sex with men in London--a community surveyIdentification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals.Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South AfricaTemporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data.Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.
P1433
Q26866452-756AAD94-6735-4303-9474-D3BD6AE65353Q27015850-8CCC1F46-B7EC-4569-B9BF-1D4EF2D6913FQ28610686-422A607E-B24A-4B21-8436-6B13A9E5068BQ28741211-76D723CD-9A0A-497D-A4C3-3355C5EDE2DEQ29307877-9B798CF6-5FBF-4B01-AA46-4687A08E6C91Q30151864-7D53A520-2F06-463A-80FA-D87BD3A6A1FAQ30344265-329D74D3-71C0-4D9A-BD80-527F09AEE3E6Q30403465-16C4AE40-ECFE-47C6-98EE-1040A1C1CDA9Q30409595-1232EB06-AD22-4843-88A9-9F4A812FA1D5Q30412422-0FA41AB6-72D8-4ACB-A134-62E22831C5D9Q30415357-F61F3238-83A0-4D65-939D-72F59161D157Q30485370-02F6389C-74C0-473E-A348-A8FA5E8DD431Q30666737-265C854A-FB43-46E8-8591-F0445B8DB041Q30692710-E7A2DCB7-DC4A-431C-8A45-9FB0D88DFD8CQ30762470-AB140B77-3928-4134-9B8F-AF9367A0497AQ30762478-2FD2D4A2-B6BB-4B66-B9A3-B63BF253442BQ30772144-19C9629E-14DD-4379-A217-3A78CCF091E8Q30863784-F96E52F8-9900-481E-85A5-88D5BA0B8137Q30881515-BEE5295E-3F29-4F31-9297-71D9B95AACACQ30881919-4DD5AC91-2759-4950-A67F-1555FD859D0DQ30894245-35F64242-C50B-437D-96E9-D4715BCFA45BQ30948574-2CFDFA6C-01A0-4889-8281-CFABE95F55D4Q30987054-EE059413-3CF2-4FA7-8C16-BBD7B9F5AD69Q31034183-53F667D4-38C2-466A-95C5-E76B5443AE67Q31055878-A8D862C5-85F2-4BF3-8DA6-C28A7CB4FEE8Q31133448-5119B3F0-FA03-46EC-9C2F-329936EA1C04Q31143771-546FC2B8-E9A9-4043-8B8C-DDEB3E8DBD0AQ33223181-CDCBC9B3-943F-400D-9D28-170EFC2873B3Q33387711-D4F66D76-711C-4E44-9341-54B48FD5044BQ33413634-F564FC66-8ECD-49F4-9A1F-1C212E02FC88Q33434277-C2D63CF3-7DA1-4319-A688-CFE3A61BA2DFQ33458818-C50ECA91-12C4-4F13-8810-E5BCE568B59FQ33593593-7A6E44A2-8C92-47AB-A1B7-DFB8D3B556B9Q33615123-E6A4DA54-F68C-4D51-8CC8-A51976C32A5FQ33632551-A551EB4E-CF81-4CD7-932A-539675C068EBQ33648600-1613FDE5-1470-4025-8506-01D0A30762D2Q33665210-BE3169D6-4EFA-45E0-A8CC-CEC22B275D15Q33667399-114BA3FD-7B95-435F-870C-BD2B48599CD7Q33669321-49897CC1-A69B-4623-8493-B24AF3088E94Q33741026-29DF7F12-786D-47E6-8A0A-BBE708581D64
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Wiley-Blackwell
@nl
مجلة
@ar
name
HIV Medicine
@ast
HIV Medicine
@da
HIV Medicine
@de
HIV Medicine
@en
HIV Medicine
@es
HIV Medicine
@fi
HIV Medicine
@fr
HIV Medicine
@it
HIV Medicine
@nb
HIV Medicine
@nl
type
label
HIV Medicine
@ast
HIV Medicine
@da
HIV Medicine
@de
HIV Medicine
@en
HIV Medicine
@es
HIV Medicine
@fi
HIV Medicine
@fr
HIV Medicine
@it
HIV Medicine
@nb
HIV Medicine
@nl
prefLabel
HIV Medicine
@ast
HIV Medicine
@da
HIV Medicine
@de
HIV Medicine
@en
HIV Medicine
@es
HIV Medicine
@fi
HIV Medicine
@fr
HIV Medicine
@it
HIV Medicine
@nb
HIV Medicine
@nl
P31
P243
P3181
P356
P1055
P1058
P1156
P1159
P123
P1250
P1277
P1476
HIV Medicine
@en
P236
P243
P3181
P356
10.1111/(ISSN)1468-1293
P407
P571
1999-01-01T00:00:00Z